612
Participants
Start Date
June 30, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
bremelanotide
"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
Site 18, New York
Site 38, Purchase
Site 77, Pittsburgh
Site 42, Philadelphia
Site 32, Washington D.C.
Site 60, Rockville
Site 9, Baltimore
Site 7, Charlottesville
Site 65, Richmond
Site 68, Norfolk
Site 47, Winston-Salem
Site 3, Raleigh
Site 49, Mt. Pleasant
Site 58, Greer
Site 55, Decatur
Site 82, Atlanta
Site 61, Orlando
Site 66, Melbourne
Site 10, Aventura
Site 1, West Palm Beach
Site 27, Fort Myers
Site 56, Birmingham
Site 26, Huntsville
Site 64, Mobile
Site 53, Chattanooga
Site 48, Lexington
Site 30, Columbus
Site 23, Beachwood
Site 19, Cleveland
Site 69, Canton
Site 71, Cincinnati
Site 81, Englewood
Site 63, South Bend
Site 70, Chicago
Site 54, Peoria
Site 74, St Louis
Site 13, Wichita
Site 35, Lincoln
Site 57, Zachary
Site 78, Hot Springs
Site 16, Jonesboro
Site 76, Dallas
Site 31, Dallas
Site 17, Houston
Site 62, San Antonio
Site 59, Corpus Christi
Site 37, Denver
Site 40, Lakewood
Site 36, Sandy City
Site 50, Murray
Site 39, Phoenix
Site 45, Chandler
Site 25, Tucson
Site 72, Las Vegas
Site 24, Las Vegas
Site 52, National City
Site 12, San Diego
Site 73, Newport Beach
Site 80, Sacramento
Site 2, Eugene
Site 22, Seattle
Site 8, Avon
Site 75, Farmington
Site 33, New London
Site 43, Warwick
Site 4, North Vancouver
Site 41, Barrie
Site 21, Burlington
Lead Sponsor
Palatin Technologies, Inc
INDUSTRY